enlivex.com (ENLV) - Long-Term Debt to Capital Coefficient

Enlivex Therapeutics (ENLV) develops cellular therapies for sepsis for intensive care units worldwide. The development of therapies for solid tumors expands the project portfolio, minimizing the probability of test failures. However, R&D costs and the risk of side effects create financial instability. The structure of long-term debt relative to equity clearly demonstrates solvency, where the 0.00 indicator expresses the state of the leverage metric.

Investors must evaluate the stability of the liability structure of Enlivex Therapeutics (ENLV) to minimize risks. This metric measures the proportion of long-term borrowings relative to equity, determining the company's degree of financial dependence. By analyzing the long-term debt-to-equity ratio, one can identify hidden debt burdens. This is critical during multi-year FDA oversight. Patent protection of the IT platform allows for capital attraction while minimizing credit risks.